1. Home
  2. FLR vs AMRX Comparison

FLR vs AMRX Comparison

Compare FLR & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fluor Corporation

FLR

Fluor Corporation

SELL

Current Price

$48.40

Market Cap

7.0B

Sector

Industrials

ML Signal

SELL

Logo Amneal Pharmaceuticals Inc.

AMRX

Amneal Pharmaceuticals Inc.

SELL

Current Price

$21.23

Market Cap

6.4B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
FLR
AMRX
Founded
1912
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.0B
6.4B
IPO Year
2006
2018

Fundamental Metrics

Financial Performance
Metric
FLR
AMRX
Price
$48.40
$21.23
Analyst Decision
Buy
Strong Buy
Analyst Count
9
7
Target Price
★ $59.56
$24.29
AVG Volume (30 Days)
2.3M
★ 3.5M
Earning Date
11-06-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 157.89
EPS
★ 3.04
0.29
Revenue
★ $15,503,000,000.00
N/A
Revenue This Year
$2.81
$6.38
Revenue Next Year
$11.01
$9.21
P/E Ratio
★ $16.15
$73.78
Revenue Growth
N/A
★ N/A
52 Week Low
$39.33
$11.39
52 Week High
$58.35
$22.07

Technical Indicators

Market Signals
Indicator
FLR
AMRX
Relative Strength Index (RSI) 49.36 57.02
Support Level $47.21 $18.90
Resistance Level $49.85 $21.21
Average True Range (ATR) 2.06 0.86
MACD 0.44 0.04
Stochastic Oscillator 61.18 71.96

Price Performance

Historical Comparison
FLR
AMRX

About FLR Fluor Corporation

Fluor is one of the largest global providers of engineering, procurement, construction, fabrication, operations, and maintenance services. It serves a wide range of end markets, including oil and gas, chemicals, mining, metals, and transportation. The company's business is organized into three core segments: urban solutions, mission solutions, and energy solutions. Fluor generated $15.5 billion in revenue in 2025.

About AMRX Amneal Pharmaceuticals Inc.

Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

Share on Social Networks: